EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sci Pharmtech's Enterprise Value is NT$6,332 Mil.
Sci Pharmtech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-390 Mil. Therefore, Sci Pharmtech's EV-to-FCF for today is -16.24.
The historical rank and industry rank for Sci Pharmtech's EV-to-FCF or its related term are showing as below:
TPE:4119'
s EV-to-FCF Range Over the Past 10 Years
Min: -129.49 Med: 10.26 Max: 1796.31
Current: -16.16
During the past 13 years, the highest EV-to-FCF of Sci Pharmtech was 1796.31. The lowest was -129.49. And the median was 10.26.
TPE:4119's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.75
vs TPE:4119: -16.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sci Pharmtech's PE Ratio (TTM) for today is calculated as:
Sci Pharmtech's share price for today is NT$45.35.
Sci Pharmtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sci Pharmtech EV-to-FCF Related Terms
Sci Pharmtech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's EV-to-FCF falls into.
Sci Pharmtech's current Enterprise Value is NT$6,332 Mil.
Sci Pharmtech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-390 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a EV-to-FCF of -16.24 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sci Pharmtech and its competitors. According to the industry distribution chart, Sci Pharmtech ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Sci Pharmtech's EV-to-FCF too high?
Sci Pharmtech's current EV-to-FCF is -16.24. Based on the distribution chart, Sci Pharmtech ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #999999 out of 564 companies for EV-to-FCF. This places Sci Pharmtech in the lower half of its industry. The industry median EV-to-FCF is 20.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.75, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current EV-to-FCF is -16.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.72, compared to a current price of NT$45.35 — trading 53.1% below its estimated fair value. The current EV-to-FCF is -16.24. Sci Pharmtech's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current EV-to-FCF is -16.24 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$45.35 is trading 53.1% below its estimated GF Value™ of NT$96.72.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
EV-to-FCF: -16.24
GF Value™: NT$96.72 vs. price of NT$45.35 (53.1% below fair value)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
